Literature DB >> 27700049

Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.

S Michael Owens1, Gerald T Pollard2, James L Howard2, Timothy R Fennell3, Rodney W Snyder3, F Ivy Carroll3.   

Abstract

JDTic is a potent and selective κ-opioid receptor (KOR) antagonist that reverses U50,488-induced diuresis in rats. It partitions into brain with a duration of action lasting for weeks. In a search for KOR antagonists that do not accumulate in the brain, we compared single doses of five methylated JDTic analogs (RTI-97, -194, -212, -240, and -241) for reversal of U50,488 diuresis and pharmacokinetic (PK) properties. All six compounds showed potent and selective KOR antagonism in a [35S]GTPγS binding assay. Plasma half-lives ranged from 24 to 41 h and brain half-lives from 24 to 76 h. JDTic and RTI-194 showed increasing brain to plasma ratios over time, indicating increasing partitioning into brain and a longer duration of action for reversal of diuresis than did RTI-97. RTI-240 did not show significant brain accumulation. RTI-212 showed no substantive difference between brain and plasma levels and was inactive against diuresis. RTI-241, with a lower brain to plasma ratio than JDTic and RTI-194, formed JDTic as a metabolite, which still reduced diuresis after 9 weeks. The fact that the duration of action was correlated with the brain to blood plasma ratios and area under the concentration-time curves suggests that PK properties could help to predict safety and acceptable duration of action for KOR antagonists.

Entities:  

Keywords:  JDTic; brain; diuresis; pharmacokinetics; prodrug; rat; κ-opioid receptor antagonist

Mesh:

Substances:

Year:  2016        PMID: 27700049      PMCID: PMC6532972          DOI: 10.1021/acschemneuro.6b00249

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  19 in total

1.  Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.

Authors:  J B Thomas; R N Atkinson; R B Rothman; S E Fix; S W Mascarella; N A Vinson; H Xu; C M Dersch; Y Lu; B E Cantrell; D M Zimmerman; F I Carroll
Journal:  J Med Chem       Date:  2001-08-16       Impact factor: 7.446

2.  Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats.

Authors:  Patrick M Beardsley; Gerald T Pollard; James L Howard; F Ivy Carroll
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

Review 3.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

4.  Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).

Authors:  Tingwei Bill Cai; Zhou Zou; James B Thomas; Larry Brieaddy; Hernán A Navarro; F Ivy Carroll
Journal:  J Med Chem       Date:  2008-02-29       Impact factor: 7.446

5.  Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.

Authors:  W C Stevens; R M Jones; G Subramanian; T G Metzger; D M Ferguson; P S Portoghese
Journal:  J Med Chem       Date:  2000-07-13       Impact factor: 7.446

6.  Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).

Authors:  Juan Pablo Cueva; Tingwei Bill Cai; S Wayne Mascarella; James B Thomas; Hernán A Navarro; F Ivy Carroll
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

7.  Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo.

Authors:  T Endoh; H Matsuura; C Tanaka; H Nagase
Journal:  Arch Int Pharmacodyn Ther       Date:  1992 Mar-Apr

8.  Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

Authors:  Ivy Carroll; James B Thomas; Linda A Dykstra; Arthur L Granger; Richard M Allen; James L Howard; Gerald T Pollard; Mario D Aceto; Louis S Harris
Journal:  Eur J Pharmacol       Date:  2004-10-06       Impact factor: 4.432

9.  Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.

Authors:  Michael R Bruchas; Tao Yang; Selena Schreiber; Mia Defino; Steven C Kwan; Shuang Li; Charles Chavkin
Journal:  J Biol Chem       Date:  2007-08-16       Impact factor: 5.157

10.  Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.

Authors:  James B Thomas; Robert N Atkinson; N Ariane Vinson; Jennifer L Catanzaro; Carin L Perretta; Scott E Fix; S Wayne Mascarella; Richard B Rothman; Heng Xu; Christina M Dersch; Buddy E Cantrell; Dennis M Zimmerman; F Ivy Carroll
Journal:  J Med Chem       Date:  2003-07-03       Impact factor: 7.446

View more
  2 in total

1.  Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).

Authors:  Pauline W Ondachi; Chad M Kormos; Scott P Runyon; James B Thomas; S Wayne Mascarella; Ann M Decker; Hernán A Navarro; Timothy R Fennell; Rodney W Snyder; F Ivy Carroll
Journal:  J Med Chem       Date:  2018-08-29       Impact factor: 7.446

2.  Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).

Authors:  Chad M Kormos; Pauline W Ondachi; Scott P Runyon; James B Thomas; S Wayne Mascarella; Ann M Decker; Hernán A Navarro; Timothy R Fennell; Rodney W Snyder; F Ivy Carroll
Journal:  J Med Chem       Date:  2018-08-29       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.